According to Menopause Solutions' February 2023 article, Semaglutide and Weight Loss, " Due to the hormonal changes associated with menopause, semaglutide is particularly effective for effective and sustained weight loss in middle-aged and menopausal women." Was this the missing piece
This is an area where open communication with your provider is especially helpful
For instance, in October 2024, Novo Nordisk made significant strides with Rybelsus, as the company announced its plan to expand the drugs indication to prevent major adverse cardiovascular events (MACE) in patients with Type 2 diabetes, cardiovascular disease (CVD), or chronic kidney disease (CKD)
Inequities in access and adherence to effective treatments have the potential to exacerbate disparities in obesity
Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women. JAMA, vol